BRISTOL MYERS SQUIBB

The global targeted protein degradation market is projected to grow from USD 0.548 billion in 2023 to USD 4.37 billion by 2034, driven by precision medicine, drug discovery investments, and technological advancements. PROTACs lead the market, with molecular glues expected to grow fastest. Therapy development dominates applications, particularly in cancer and neurodegenerative diseases. Pharmaceutical & biotechnology companies are the largest end-users. North America leads in revenue, while Asia-Pacific shows the highest growth rate.

Aspargo Labs appoints Álvaro Fernández in Spain and Dr. Marc van Unen in Germany to accelerate global expansion, leveraging their pharmaceutical industry expertise.

Aspargo Labs appoints Álvaro Fernández and Dr. Marc van Unen as General Managers in Spain and Germany to drive global expansion. Both bring extensive pharmaceutical experience to accelerate the company's international growth.

Merck licenses a GLP-1 candidate from Hansoh Pharma; Astellas collaborates with Sangamo for gene therapy; Betta Pharma's Ensacove gains FDA approval for lung cancer; Mitsubishi Tanabe attracts buyout interest; BeiGene licenses a MAT2A inhibitor; Candid Therapeutics forms new collaborations; BMS regains China rights to a RayzeBio candidate.

Intas Pharmaceuticals' U.S. division, Accord BioPharma, acquires Coherus BioSciences' UDENYCA® biosimilar to expand its portfolio. Intas also partners with Xbrane for a nivolumab biosimilar, aiming for launch post-patent expiration.

Joining a lupus clinical trial offers potential access to new treatments and contributes to research, but involves uncertainty and may require stopping current medications. Close monitoring and communication with researchers are key, as is prioritizing personal health. Patients should feel empowered to drop out if needed.

Participating in lupus clinical trials offers access to potential new treatments, though concerns about misconceptions and uncertainties exist. Trials vary in focus, from treatment efficacy to quality of life, and participation can significantly improve patient outcomes. The informed consent process ensures understanding of trial details, risks, and benefits, with opportunities to ask questions and withdraw if needed. Key considerations include trial duration, treatment specifics, and compensation. Proactive research and support systems are crucial for informed decision-making and successful participation.

2024 saw major medical advancements: FDA approved Orlynvah for UTIs, Cobenfy for schizophrenia, and Miplyffa/Aqneursa for Niemann-Pick disease type C. Bayer's elinzanetant showed promise for hot flashes.

Imbed Biosciences appoints Terry Bromley as CEO, leveraging his 30+ years in medical devices and wound care to advance the company's Microlyte® Matrix technology and revolutionize infection solutions and wound care, aiming to improve patient outcomes and drive growth in the healthcare industry.